Coherus BioSciences’ (CHRS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $12.00 target price on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Truist Financial reduced their price target on Coherus BioSciences from $8.00 to $7.00 and set a buy rating on the stock in a research note on Monday, May 13th. StockNews.com cut shares of Coherus BioSciences from a buy rating to a hold rating in a research report on Friday, July 26th. Finally, Robert W. Baird dropped their price objective on shares of Coherus BioSciences from $9.00 to $8.00 and set an outperform rating on the stock in a research note on Monday, July 1st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average target price of $8.00.

Coherus BioSciences Stock Up 4.0 %

Shares of Coherus BioSciences stock opened at $1.29 on Monday. The business has a 50 day moving average of $1.59 and a 200 day moving average of $2.04. Coherus BioSciences has a 52 week low of $1.22 and a 52 week high of $5.47. The company has a market cap of $148.00 million, a PE ratio of -1.65 and a beta of 0.60.

Coherus BioSciences (NASDAQ:CHRS) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.33). The business had revenue of $77.06 million for the quarter, compared to analyst estimates of $102.00 million. During the same period in the previous year, the business earned ($0.89) EPS. On average, research analysts anticipate that Coherus BioSciences will post -1.14 earnings per share for the current year.

Hedge Funds Weigh In On Coherus BioSciences

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Coherus BioSciences by 10.5% in the third quarter. Vanguard Group Inc. now owns 9,782,127 shares of the biotechnology company’s stock worth $36,585,000 after buying an additional 932,476 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Coherus BioSciences during the fourth quarter valued at approximately $244,000. China Universal Asset Management Co. Ltd. raised its holdings in Coherus BioSciences by 430.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,880 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 10,454 shares during the last quarter. International Assets Investment Management LLC lifted its position in Coherus BioSciences by 934.3% in the 4th quarter. International Assets Investment Management LLC now owns 142,491 shares of the biotechnology company’s stock valued at $474,000 after acquiring an additional 128,715 shares in the last quarter. Finally, Carr Financial Group Corp bought a new stake in shares of Coherus BioSciences in the 4th quarter worth $117,000. Institutional investors own 72.82% of the company’s stock.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.